- A +

Events › 2017

19 - 22Jun.2017

BIO International ConventionSan Diego, CA US

GenSight will attend and host partnering meetings. 

28 - 31May2017

ISCAS 2017 (IEEE International Symposium on Circuits And Systems), Baltimore Maryland (US)

GenSight will give an oral presentation and a demonstration on its stimulation platform for optogenetic and bionic vision restoration.

A Stimulation Platform for Optogenetic and Bionic Vision Restoration

Oral presentation : Integrated Biomedical Systems, BioMEMS & Biosensors/Actuators I Lecture session B3L-J, # 1678

"Live Demonstration: a Stimulation Platform for Optogenetic and Bionic Vision Restoration"

Demo presentation:  Demonstration Session II Poster session B4P-O, # 2524

07 - 11May2017

2017 ARVO Annual Meeting, Baltimore, Maryland (US)

The company will present several posters on both its lead products and an oral presentation on its GS030 optogenetics product.

- GS010 aiming at treating LHON, a rare mitochondrial genetic disease

Phase I/IIa Visual Acuity Outcomes 1.5-Years Post-Treatment with rAAV2/2-ND4, an Investigational Gene Therapy for ND4 LHON.

Poster session:  Wednesday 10 May, 2017, 11.00am – 12.45pm, Session Low Vision Populations, Services and Treatments, Posterboard #: B0588, Abstract Number: 4681 - B0588

Preliminary Baseline Characteristics of Patients with Leber Hereditary Optic Neuropathy (LHON) Enrolled in the RESCUE and REVERSE Clinical Gene Therapy Trials. 

Poster session: Wednesday 10 May, 2017, 8.30am – 10.15am, Session Optic Neuropathy, Posterboard #: A0036, Abstract Number: 3865 - A0036

- GS030 based on optogenetics to treat RP

Long term visual restoration using optogenetic engineering of retinal ganglion cells with AAV2.7m8- ChrimsonR-tdTomato

Oral presentation:  Tuesday 9 May, 9.15-9.30 am, Session Diseases and Protection, Abstract Number # 1219

Visual acuity and optical flow in primate retinal ganglion cells treated with an optogenetic vision restoration strategy using ChrimsonR

Poster session:  Thursday 11 May, 2017, 11.30am – 1.15pm, Session Visual Disease Models and Restoration, Posterboard # B0475 - Abstract Number: 5883 - B0475

Modeling the dynamics of light-driven microbial opsin ChrimsonR

Poster session:  Thursday 11 May, 2017, 11.30am – 1.15pm, Session Visual Disease Models and Restoration, Posterboard # B0465 - Abstract Number: 5873 - B0465

03 - 04May2017

Deutsche Bank 42nd Annual Health Care Conference, Boston (MA), US

Bernard Gilly, Chief Executive Officer and Thomas Gidoin, Chief Financial Officer will present on May 4, 2017, at 9:20am EST, at the InterContinental Boston Hotel and will host investor meetings.

22 - 28Apr.2017

American Academy of Neurology 69th Annual Meeting (AAN)

GenSight will give an oral presentation entitled "Intravitreal rAAV2/2-ND4 (GS010): A gene therapy for vision loss in Leber's Hereditary Optic Neuropathy (LHON) caused by the G11778A ND4 mitochondrial mutation" (Abstract number #2444) in Session S26: Neuro-ophthalmology/Neuro-Otology on April 25, 2017, at 4:18 PM (platform presentation number  005).

27Apr.2017

5th Annual ARM Cell&Gene Investor Day, Boston (MA), US

Bernard Gilly, Chief Executive Officer and Thomas Gidoin, Chief Financial Officer will present at the ARM Cell&Gene Investor Day in Boston, MA, USA on Thursday, April 27, 2017, at 4:45 pm ET, The State Room, and will host investor meetings.

01 - 06Apr.2017

43rd NANOS Annual Meeting (North American Neuro-Ophthalmology Society)

GenSight gave an oral presentation and presented two posters on its lead product GS010 currently in Phase 3 in Europe and US aiming at treating LHON, a rare mitochondrial genetic disease

Both posters were presented at the session “Poster Session II: Scientific Advancements in Neuro-Ophthalmology” in the Category: Disorders of the Anterior Visual Pathway (Retina, Optic Nerve, and Chiasm) on Tuesday, April 4, 2017 from 6:00 -9:30 pm, Room Location: Exhibit Hall C

Title:  Pediatric Leber Hereditary Optic Neuropathy (LHON): A Literature Review (Poster Number # 186)

Title:  Preliminary Baseline Characteristics of Patients with LHON Enrolled in RESCUE and REVERSE Gene Therapy Trials (Poster Number # 189)

Presentation took place on Tuesday, April 4th from 10:00am- 10:15am, in the Thurgood Marshall Ballroom

Title:  Phase I/IIa Visual Acuity Outcomes 1.5-Years Post-Treatment with rAAV2/2-ND4, Investigational Gene Therapy for ND4 LHON.

09 - 12Jan.2017

JP Morgan 35th Annual Healthcare Conference, San Francisco (CA), USA

Bernard Gilly, Chief Executive Officer and Thomas Gidoin, Chief Financial Officer hosted investor meetings. GenSight took this opportunity to meet with a numerous partners and companies. 

05 - 06Jan.2017

Oddo 20th Forum – Lyon, France

Bernard Gilly, Chief Executive Officer and Thomas Gidoin, Chief Financial Officer hosted investor meetings at the 20th Oddo Forum in Lyon, France on January 5-6, 2017